Repligen (RGEN) Competitors $114.87 -4.64 (-3.89%) As of 11:57 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock RGEN vs. TECH, A, DHR, TMO, BIIB, INCY, NBIX, UTHR, BMRN, and EXELShould you be buying Repligen stock or one of its competitors? The main competitors of Repligen include Bio-Techne (TECH), Agilent Technologies (A), Danaher (DHR), Thermo Fisher Scientific (TMO), Biogen (BIIB), Incyte (INCY), Neurocrine Biosciences (NBIX), United Therapeutics (UTHR), BioMarin Pharmaceutical (BMRN), and Exelixis (EXEL). These companies are all part of the "medical" sector. Repligen vs. Its Competitors Bio-Techne Agilent Technologies Danaher Thermo Fisher Scientific Biogen Incyte Neurocrine Biosciences United Therapeutics BioMarin Pharmaceutical Exelixis Repligen (NASDAQ:RGEN) and Bio-Techne (NASDAQ:TECH) are both mid-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, media sentiment, earnings, valuation, institutional ownership, risk and dividends. Do insiders and institutionals have more ownership in RGEN or TECH? 97.6% of Repligen shares are owned by institutional investors. Comparatively, 99.0% of Bio-Techne shares are owned by institutional investors. 1.2% of Repligen shares are owned by company insiders. Comparatively, 3.9% of Bio-Techne shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term. Does the media refer more to RGEN or TECH? In the previous week, Bio-Techne had 2 more articles in the media than Repligen. MarketBeat recorded 17 mentions for Bio-Techne and 15 mentions for Repligen. Repligen's average media sentiment score of 1.39 beat Bio-Techne's score of 1.16 indicating that Repligen is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Repligen 10 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Bio-Techne 11 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do analysts rate RGEN or TECH? Repligen presently has a consensus target price of $166.67, suggesting a potential upside of 44.81%. Bio-Techne has a consensus target price of $70.42, suggesting a potential upside of 38.30%. Given Repligen's higher possible upside, analysts plainly believe Repligen is more favorable than Bio-Techne.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Repligen 0 Sell rating(s) 4 Hold rating(s) 8 Buy rating(s) 0 Strong Buy rating(s) 2.67Bio-Techne 0 Sell rating(s) 4 Hold rating(s) 8 Buy rating(s) 1 Strong Buy rating(s) 2.77 Is RGEN or TECH more profitable? Bio-Techne has a net margin of 6.02% compared to Repligen's net margin of -2.05%. Bio-Techne's return on equity of 13.43% beat Repligen's return on equity.Company Net Margins Return on Equity Return on Assets Repligen-2.05% 4.61% 3.24% Bio-Techne 6.02%13.43%10.32% Which has more volatility & risk, RGEN or TECH? Repligen has a beta of 1.07, indicating that its stock price is 7% more volatile than the S&P 500. Comparatively, Bio-Techne has a beta of 1.47, indicating that its stock price is 47% more volatile than the S&P 500. Which has higher earnings & valuation, RGEN or TECH? Bio-Techne has higher revenue and earnings than Repligen. Repligen is trading at a lower price-to-earnings ratio than Bio-Techne, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioRepligen$673.96M9.61-$25.51M-$0.25-460.37Bio-Techne$1.22B6.54$73.40M$0.46110.69 SummaryBio-Techne beats Repligen on 13 of the 16 factors compared between the two stocks. Get Repligen News Delivered to You Automatically Sign up to receive the latest news and ratings for RGEN and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding RGEN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart RGEN vs. The Competition Export to ExcelMetricRepligenMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$6.48B$3.18B$5.80B$10.16BDividend YieldN/A2.32%5.69%4.61%P/E Ratio-460.4721.4874.7325.99Price / Sales9.61301.34470.3491.76Price / Cash38.7045.3337.0859.91Price / Book3.279.6312.256.31Net Income-$25.51M-$53.32M$3.28B$270.66M7 Day Performance-7.60%0.95%1.39%3.52%1 Month Performance-5.20%9.68%7.70%6.79%1 Year Performance-18.91%13.38%64.01%28.29% Repligen Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)RGENRepligen4.8988 of 5 stars$115.09-3.7%$166.67+44.8%-16.7%$6.48B$673.96M-460.471,778Positive NewsAnalyst ForecastTECHBio-Techne4.9902 of 5 stars$54.63+0.6%$69.42+27.1%-27.6%$8.56B$1.22B118.763,100Positive NewsAAgilent Technologies4.6733 of 5 stars$125.63+0.5%$139.25+10.8%-8.5%$35.70B$6.51B29.4917,900Positive NewsDHRDanaher4.9888 of 5 stars$206.09+0.4%$247.61+20.1%-28.2%$147.38B$23.88B43.8563,000News CoveragePositive NewsDividend AnnouncementTMOThermo Fisher Scientific4.963 of 5 stars$493.05+0.7%$593.00+20.3%-20.6%$186.06B$42.88B28.52125,000Trending NewsAnalyst UpgradeInsider TradeAnalyst RevisionBIIBBiogen4.6532 of 5 stars$132.22-0.3%$185.74+40.5%-25.2%$19.39B$9.68B12.647,605Positive NewsINCYIncyte4.7681 of 5 stars$84.61+1.1%$81.60-3.6%+36.5%$16.52B$4.24B19.232,617Positive NewsShort Interest ↓NBIXNeurocrine Biosciences4.7318 of 5 stars$139.60+0.5%$159.50+14.3%+18.2%$13.85B$2.36B41.301,800Positive NewsUTHRUnited Therapeutics4.8067 of 5 stars$304.76-0.8%$382.00+25.3%+16.9%$13.75B$2.88B11.901,305News CoveragePositive NewsAnalyst ForecastInsider TradeAnalyst RevisionBMRNBioMarin Pharmaceutical4.9525 of 5 stars$58.27+1.0%$93.17+59.9%-34.1%$11.19B$2.85B17.293,040Short Interest ↑EXELExelixis4.7283 of 5 stars$37.42-1.3%$44.06+17.7%+46.7%$10.07B$2.17B17.991,147Positive News Related Companies and Tools Related Companies Bio-Techne Alternatives Agilent Technologies Alternatives Danaher Alternatives Thermo Fisher Scientific Alternatives Biogen Alternatives Incyte Alternatives Neurocrine Biosciences Alternatives United Therapeutics Alternatives BioMarin Pharmaceutical Alternatives Exelixis Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:RGEN) was last updated on 9/12/2025 by MarketBeat.com Staff From Our PartnersStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredTrump’s Plan May Undo 1933’s Biggest Financial InjusticeTrump's Reset Can Give Birth To America's Greatest Era Yet A 90-Year cycle may end soon, creating real weal...American Hartford Gold | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredAlert: Prepare for Trump's Dollar OverhaulPresident Trump just signed a game-changing law… That could soon upgrade the U.S. dollar in your checking a...Brownstone Research | SponsoredNVDA: The cracks are beginning to showThe media hasn't caught up to the story yet, but when they do, this stock could leave Nvidia in the dust. I...InvestorPlace | SponsoredForget NVDA. Put $1,000 into this stock nowA massive money shift is underway in the AI market. And it's opening up an extraordinary opportunity in a NEW ...Chaikin Analytics | SponsoredGENIUS Act: The Plot to Seize Your Cash?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Repligen Corporation Please log in to your account or sign up in order to add this asset to your watchlist. Share Repligen With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free RGEN Stock Alerts